Soligenix Inc (SNGX.OQ)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|48||2009||Chairman of the Board, President, Chief Executive Officer|
|60||2016||Chief Financial Officer, Senior Vice President|
|43||2014||Senior Vice President, Chief Scientific Officer|
|63||2014||Senior Vice President and Chief Medical Officer|
- BRIEF-Soligenix Receives Orphan Drug Designation From The European Commission For Rivax For Prevention Of Ricin Poisoning
- BRIEF-Soligenix Says As Of Dec. 31, 2017, Cash Position Was $7.8 Mln
- BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials
- BRIEF-Soligenix Announces US Patent Issuance For Use Of Dusquetide In Oral Mucositis
- BRIEF-Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule